CYP2D6 and Dystonia: In one study of the drug risperidone, intermediate metabolizers with the *41 allele showed increased levels of the drug and its metabolites (nearly twofold versus poor, or CYP2D6 loss-of-function metabolizers, which show threefold) with an increased risk of developing dystonia and parkinsonism adverse effects [5].